Full Press Release Details
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation.
REGN
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
Key Takeaway: U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation